(BUSINESS WIRE)--Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that The Journal of Molecular Diagnostics (JMD) has published the results of a significant Tissue of Origin Test validation and reproducibility study. In the large blinded, multi-site study employing 462 formalin-fixed, paraffin-embedded (FFPE) tumor specimens, the Tissue of Origin Test results were in agreement with the available diagnosis in 89% of cases. These results show that the gene expression based Tissue of Origin Test can assist in accurately and reliably identifying the origin of metastatic or poorly differentiated tumors using FFPE tissue, which is the most common clinical specimen type used in testing of cancer tumors.
